Yuan Pan

Yuan Pan

Auto-generated profile, based on publicly available information

Yuan Pan

Key Laboratory of Stem Cells and Tissue Engineering (Ministry of Education), Zhongshan School of Medicine, and

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
YQYi Qiu
Yi Qiu
MSMengxi Su
Mengxi Su
LLLeyi Liu
Leyi Liu
YTYiqi Tang
Yiqi Tang
YPYuan Pan
Yuan Pan
JSJianbo Sun
Jianbo Sun
Cytokines are key components of the immune system and play pivotal roles in anticancer immune response. Cytokines as either therapeutic agents or targets hold clinical promise for cancer precise treatment. Here, we provide an overview of the various roles of cytokines in the cancer immunity cycle, with a particular focus on the clinical researches of cytokine-based drugs in cancer therapy. We review 27 cytokines in 2630 cancer clinical trials registered with ClinicalTrials.gov that had completed recruitment up to January 2021 while summarizing important cases for each cytokine. We also discuss recent progress in methods for improving the delivery efficiency, stability, biocompatibility, and availability of cytokines in therapeutic applications.

26 May 2022 in Blood
Verified
Journal Article
Closed access
PDF file
QLQi Lou
Qi Lou
KJKaizheng Jiang
Kaizheng Jiang
QXQuanhui Xu
Quanhui Xu
LYLisha Yuan
Lisha Yuan
SXSiyu Xie
Siyu Xie
MZMeng Zhao
Meng Zhao
Bone marrow–derived mesenchymal stem cells (BMSCs) support bone formation and constitute the stromal niche in regulating hematopoietic stem cells (HSCs). Stromal niche dysfunction affects HSC engraftment during transplantation; however, the underlying mechanisms remain elusive. In the present study, we found that all-trans retinoic acid (ATRA) and inflammation stress upregulated retinoic acid–inducible gene I (RIG-I) in BMSCs. Excess RIG-I expression damaged the clonogenicity, bone-forming ability of BMSCs and particularly their stromal niche function that supports HSC expansion in vitro and engraftment in vivo. Mechanistically, RIG-I elevation promoted the degradation of NRF2, a checkpoint for antioxidant cellular response, by altering the RIG-I-Trim25-Keap1-NRF2 complex, leading to reactive oxygen species (ROS) accumulation and BMSC damage. Genetic inhibition of RIG-I sustained NRF2 protein levels and reduced ROS levels in ATRA-treated BMSCs, thus preserving their clonogenicity, bone-forming ability, and stromal niche function in supporting HSC engraftment in mice. More importantly, RIG-I inhibition recovered the ATRA-treated stromal niche function to enhance HSC engraftment and emergency myelopoiesis for innate immunity against the bacterium Listeria monocytogenes during transplantation. Overall, we identified a noncanonical role of RIG-I in the regulation of the stromal niche for HSC transplantation.

1 February 2022 in JAMA Ophthalmology
Verified
Journal Article
Closed access
PDF file
YLYao Lu
Yao Lu
YPYuan Pan
Yuan Pan
DLDan Liang
Dan Liang
A 42-year-old Chinese woman presented with bilateral visual acuity of hand motion OU, headache, and tinnitus for 1 month before presentation. Vogt-Koyanagi-Harada (VKH) syndrome was diagnosed based on imaging abnormalities after infection, and a history of ocular trauma or surgery was excluded. After receiving prednisone (1.2 mg/kg per day with slow taper) and cyclosporine (4.5 mg/kg per day), the patient’s visual acuity improved to 20/100 OD and 20/200 OS. In addition, her tinnitus resolved, but her headache persisted. Bilateral, massive, streaklike subretinal fibrosis and multiple serous retinal detachments were demonstrated by multimodal imaging after 3 months of treatment; the left eye is shown in the Figure. The fluorescein angiograph revealed blocked fluorescence in the areas of fibrosis from the prearterial through the late recirculation phases. Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.